Eli Lilly & Company
Eli Lilly & Company
Caproasia.com | The leading source of data, research, information & resource for financial professionals, investment managers, professional investors, family offices & advisors to institutions, billionaires, UHNWs & HNWs. Covering capital markets, investments and private wealth in Asia. How do you invest $3 million to $300 million? How do you manage $20 million to $3 billion of assets? Caproasia - Learn more



This site is for accredited investors, professional investors, investment managers and financial professionals only. You should have assets around $3 million to $300 million or managing $20 million to $30 billion.











United States $808 Billion Biopharmaceutical Giant Eli Lilly Buys United States Clinical-Stage Biotechnology Company Kelonia Therapeutics for $7 Billion in All-Cash Deal ($3.25 Billion Upfront & $3.75 Billion Contingents), Kelonia Therapeutics Founded in 2022 by Massachusetts Institute of Technology (MIT) Professor Michael Birnbaum & Stanford University Professor Michael Fischbach

22nd April 2026 | Hong Kong

United States biopharmaceutical giant Eli Lilly ($808 billion market value) has announced to buy United States clinical-stage biotechnology company Kelonia Therapeutics $7 billion ($3.25 billion upfront & $3.75 billion contingents) in all-cash deal.  Kelonia Therapeutics was founded in 2022 by Massachusetts Institute of Technology (MIT) Associate Professor of Biological Engineering Michael Birnbaum, Ph.D. and Stanford University Associate Professor of Bioengineering Michael Fischbach, Ph.D. (Founded as Viralogic Therapeutics in 2020).  Kelonia Therapeutics – Kelonia Therapeutics is a clinical-stage biotechnology company pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS®). Kelonia’s elegant, cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modification to improve in vivo gene transfer efficiency and tropism molecules to facilitate tissue-specific delivery. Kelonia is building a pipeline of genetic medicines across a range of diseases, with the bold goal of making CAR-T cell therapies accessible to every patient in need, when and where they need them. Kelonia’s lead candidate, KLN-1010, is an in vivo anti-BCMA CAR-T therapy for multiple myeloma being evaluated in a Phase 1 clinical trial. Kelonia was incubated and seed funded by Venrock.  Eli Lilly – Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people.

“ United States $808 Billion Biopharmaceutical Giant Eli Lilly Buys United States Clinical-Stage Biotechnology Company Kelonia Therapeutics for $7 Billion in All-Cash Deal ($3.25 Billion Upfront & $3.75 Billion Contingents), Kelonia Therapeutics Founded in 2022 by Massachusetts Institute of Technology (MIT) Professor Michael Birnbaum & Stanford University Professor Michael Fischbach “

 



- Article continues below -



Intelligence at your fingertips
Get Started ($29 per year) : Click here
Caproasia Subscription ($680 yearly | $70 monthly): Click here


The 2026 Investment Day
Hong Kong | Singapore
March / July / Sept / Oct / Nov

Private Equity, Hedge Funds, Boutique Funds, Private Markets & more. Join 20+ CIOs & Senior investment team, with > 60% single family offices with $300 million AUM. Taking place in Hong Kong and in Singapore. Every March, April, July, Sept, Oct & Nov.
Visit | Register here


The 2026 Family Office Summit
9th / 16th April & 15th Oct Hong Kong Ritz Carlton | 23rd / 30th April & 5th Nov Singapore Amara Sanctuary Resort

Join 60 single family offices & family office professionals in Hong Kong & Singapore
Links: 2026 Family Office Summit | Register here


2026 Investment / Alternatives Summit
March / Oct / Nov in Hong Kong & Singapore

Join leading asset managers, hedge funds, boutique funds, private equity, venture capital & real estate firms in Hong Kong, Singapore & Asia-Pacific at the Investment / Alternatives Summit. Join as delegate, speaker, presenter, partner & sponsor.
Visit | Register here


2026 Private Wealth Summit
April / Oct / Nov in Hong Kong & Singapore

Join CEOs, CIOs, Head of Private Banking, Head of Family Offices & Product Heads at The Private Wealth Summit.  Join as delegate, speaker, presenter, partner & sponsor.
Visit | Register here





 

United States $808 Billion Biopharmaceutical Giant Eli Lilly Buys United States Clinical-Stage Biotechnology Company Kelonia Therapeutics for $7 Billion in All-Cash Deal ($3.25 Billion Upfront & $3.75 Billion Contingents), Kelonia Therapeutics Founded in 2022 by Massachusetts Institute of Technology (MIT) Professor Michael Birnbaum & Stanford University Professor Michael Fischbach

Eli Lilly & Company
Eli Lilly & Company



Managing $20 million to $3 billion. Investing $3 million to $300 million.
For Investment Managers, Hedge Funds, Boutique Funds, Private Equity, Venture Capital, Professional Investors, Family Offices, Private Bankers & Advisors, sign up today. Subscribe to Caproasia and receive the latest news, data, insights & reports, events & programs daily at 2 pm.

Join Events & Find Services
Join Investments, Private Wealth, Family Office events in Hong Kong, Singapore, Asia-wide. Find hard-to-find $3 million to $300 million financial & investment services at The Financial Centre | TFC. Find financial, investment, private wealth, family office, real estate, luxury investments, citizenship, law firms & more.  List hard-to-find financial & private wealth services.

Have a product launch? Promote a product or service? List your service at The Financial Centre | TFC. Join interviews & editorial and be featured on Caproasia.com or join Investments, Private Wealth, Family Office events. Contact us at [email protected] or [email protected]

Caproasia.com | The leading source of data, research, information & resource for financial professionals, investment managers, professional investors, family offices & advisors to institutions, billionaires, UHNWs & HNWs. Covering capital markets, investments and private wealth in Asia. How do you invest $3 million to $300 million? How do you manage $20 million to $3 billion of assets?



Quick Links



Web links may be disabled on mobile for security.
Please click on desktop.










Caproasia Users

  • Manage $20 million to $30 billion of assets
  • Invest $3 million to $300 million
  • Advise institutions, billionaires, UHNWs & HNWs

Caproasia Platforms | 11,000 Investors & Advisors

Monthly Roundtable & Networking

Family Office Programs

The 2026 Investment Day

  • March - Hong Kong
  • March - Singapore
  • April - Hong Kong
  • April - Singapore
  • July - Hong Kong
  • July - Singapore
  • Sept- Hong Kong
  • Sept - Singapore
  • Oct- Hong Kong
  • Nov - Singapore
  • Visit: The Investment Day | Register: Click here

Caproasia Summits

Contact Us

For Enquiries, Membership
[email protected], [email protected]

For Listing, Subscription
[email protected], [email protected]

For Press Release, send to:
[email protected]

For Events & Webinars
[email protected]

For Media Kit, Advertising, Sponsorships, Partnerships
[email protected]

For Research, Data, Surveys, Reports
[email protected]

For General Enquiries
[email protected]





Caproasia | Driving the future of Asia
a financial information technology co.
since 2014